Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

141 results about "Fluorouracil" patented technology

This medication is used on the skin to treat pre-cancerous and cancerous skin growths.

Application of MK2206 in preparation of medicine for treating colorectal cancer

The invention relates to the field of tumor treatment, in particular to application of a small molecule compound in preparation of a medicine for treating colorectal cancer. The AKT pathway specific inhibitor MK2206 disclosed by the invention can inhibit the proliferation of colorectal cancer, induce cell cycle arrest, induce apoptosis and enhance the sensitivity of colorectal cancer cells to oxaliplatin and 5-fluorouracil. The MK2206 is used for inhibiting the activity of an AKT pathway, so that the effects of inhibiting proliferation of colorectal cancer cells, inducing apoptosis of the colorectal cancer cells and improving the sensitivity of the colorectal cancer cells to chemotherapeutic drugs oxaliplatin and 5-fluorouracil are achieved, and the MK2206 can be used for preparing drugs for treating the colorectal cancer.
Owner:JINAN MICROECOLOGY & BIOMEDICINE PROVINCIAL LAB

Paeonol Mannich base-rhein conjugate as well as preparation method and application thereof

The invention belongs to the technical field of medicinal chemistry, and discloses a paeonol mannich base-rhein conjugate as well as a preparation method and application thereof. The conjugate is a compound as shown in a general formula (I) or (II) or a pharmaceutically acceptable salt thereof. Compared with the clinically common antitumor drugs fluorouracil and paeonol, the conjugate provided by the invention has obviously higher in-vitro anti-human hepatoma carcinoma cell (HepG2) and human lung cancer cell (A549) proliferative activity, and the in-vitro anti-human cervical carcinoma cell (Hela), human colon cancer cell (HT29) and human osteosarcoma cell (U2OS) proliferative activity of most compounds is obviously superior to that of fluorouracil and paeonol; and the conjugate has good water solubility, is expected to be applied to treatment of various cancers such as cervical cancer, colon cancer, osteosarcoma, lung cancer or liver cancer, and has a wide clinical application prospect. # imgabs0 #
Owner:ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

Method, system and equipment for evaluating treatment effect of PTT on pancreatic cancer

The invention discloses a method, a system and equipment for evaluating the treatment effect of PTT on pancreatic cancer. According to the application disclosed by the invention, PTT is found to treat pancreatic cancer by regulating a caspase-1 / GSDMD pathway for the first time, and the expression level of GSDMD is found to be in positive correlation with the drug resistance of pancreatic cancer cells to 5-fluorouracil, irinotecan, paclitaxel and cis-platinum, which prompts that people can adopt a local treatment method of photothermal therapy instead of traditional chemotherapy for patients with high expression of GSDMD. Besides, the invention provides a method, a system and equipment for evaluating the treatment effect of PTT on pancreatic cancer and a method, a system and equipment for predicting the sensitivity of pancreatic cancer patients to chemotherapeutics, thereby assisting doctors in evaluating the treatment effect of pancreatic cancer patients and guiding clinicians to formulate individualized treatment schemes for patients.
Owner:THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL

Cyclic deoxyribonucleotide compounds

Provided herein are 5-fluorouracil derived cyclic deoxyribonucleotide compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.
Owner:NUCORION PHARMACEUTICALS INC

Classifying an entity for FOLFOX treatment

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that strongly correlate with response of colorectal cancer patients to FOLFOX. Described herein are data structures, data processing, and machine learning models to predict effectiveness of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising administration of 5-fluorouracil / leucovorin combined with oxaliplatin (FOLFOX) or with irinotecan (FOLFIRI).
Owner:CARIS MPI INC

Application of spermidine alkaloid in preparation of antitumor drugs and / or reversal of drug resistance

The invention belongs to the technical field of natural medicines, and particularly relates to application of spermidine alkaloid in preparation of anti-tumor medicines and / or reversion of drug resistance. The invention provides an application of macrocyclic spermidine alkaloid in preparation of anti-tumor drugs and / or reverse drug resistance. The macrocyclic spermidine alkaloid comprises one or more than two of 13-oxo-furan celastrus orbiculatus, furan celastrus orbiculatus, benzene-substituted celastrus orbiculatus and celastrus orbiculatus cinnamamide alkali. The macrocyclic spermidine alkaloid disclosed by the invention has the characteristics of broad-spectrum anti-tumor effect, good anti-tumor effect, relatively low toxic and side effects, capability of reversing 5-fluorouracil drug resistance, relatively high water solubility, relatively easy source, simple structure, only one chiral carbon in the structure, relatively easy artificial synthesis, intervention in cell autophagy mechanism and the like, so that the overall treatment cost is relatively low; the method has a potential important clinical application prospect.
Owner:JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

Application of chalcone compound in preparation of medicine for treating cervical cancer

The invention belongs to the technical field of disease drug treatment, and particularly relates to application of a chalcone compound in preparation of drugs for treating cervical cancer. The chalcone compound can remarkably inhibit cervical cancer cells, so that the growth of cervical cancer tumors is effectively inhibited; and the effect is better than that of the existing antitumor drug 5-fluorouracil.
Owner:BEIJING UNIV OF CHINESE MEDICINE

(9beta-h)-pimarane mother nucleus diterpenoid compound with Anti-colon cancer activity and derivative thereof, and preparation method thereof

The invention discloses a (9β-H)-pimarane skeleton diterpenoids with anti-colon cancer activity and a derivative thereof, and further discloses a preparation method and application of the compounds above; the invention finds that novel skeleton compounds 1 and 2 have certain inhibition effects on colon cancer cells, wherein the compound 2 has remarkable anti-proliferation effects on two colon cancer cell lines HT-29 and SW620, and the effects are both stronger than those of a positive drug 5-fluorouracil, so that the compound has the potential of being developed into a new anti-colon cancer drug.
Owner:NANJING UNIV OF TRADITIONAL CHINESE MEDICINE

Five-membered sulfur-containing heterocyclic nucleoside lead compound and application thereof in resisting cervical cancer and pancreatic cancer activity

The invention discloses a five-membered sulfur-containing heterocyclic nucleoside lead compound and application thereof in resisting cervical cancer, pancreatic cancer and other activities, and belongs to the technical field of medicinal chemistry. A series of five-membered sulfur-containing heterocyclic ring nucleoside compounds are synthesized through a two-step Michael addition reaction, and the five-membered sulfur-containing heterocyclic ring nucleoside compounds comprise a racemate, (3S, 4R) and (3R, 4S): # imgabs0 # (* is a chiral center). Results show that in in-vitro cervical cancer (HeLa), pancreatic cancer (PANC-1) and other cell tests, the anti-tumor activity of the racemate is close to that of the enantiomer configuration. Wherein the chiral five-membered sulfur-containing heterocyclic nucleoside lead compound (3R, 4S)-15ab shows relatively strong proliferation inhibition capacity in a cervical cancer cell line, and IC50 (half maximal inhibitory concentration) reaches 2.78 mu M and is obviously superior to that of control drugs 5-fluorouracil and cis-platinum (IC50 is 9.75 mu M and 7.99 mu M respectively).
Owner:HENAN NORMAL UNIV

2-substituted benzylhydrazino-4-indolyl pyrimidine-5-carbonitrile derivatives and methods for their preparation

The application discloses a kind of 2-substituted benzylhydrazine-4-indole pyrimidine-5-carbonitrile derivatives and preparation method and application thereof.The derivative has general formula (I) structure: wherein R is hydroxyl or C1-C4 alkoxy, n=1~3.Preferred compound is 2-hydroxy, 4-hydroxy-3-methoxy, 2,3-dihydroxy or 2,4-dihydroxy substituted benzylhydrazine derivative.The application also provides key intermediate 2-hydrazine-4-(1H-indole-3-carbonyl) pyrimidine-5-carbonitrile and preparation method thereof.In vitro antitumor activity shows that the derivative has excellent inhibitory activity on human gastric cancer cell MGC-803, and the inhibition rate is up to 96.3% at 10 μmol / L, which is better than positive control doxorubicin.In vivo combination test shows synergistic effect with 5-fluorouracil or anti-PD-1 antibody.The compound of the application has mild synthesis route, high yield, various preparation forms, good safety, and can be applied in the preparation of anti-gastric cancer drugs.
Owner:NINGXIA YUANCHENG BIOTECHNOLOGY CO LTD

Flurala drop preparation method based on online monitoring

The invention relates to the technical field of production of flurala drops, in particular to a flurala drop preparation method based on online monitoring. The preparation method comprises the following preparation processes: sequentially adding weighed dimethylacetamide and acetone into a liquid preparation tank, adding fluralana and tetrahydrofuran polyglycol ether into the liquid preparation tank, stirring until the materials are uniformly mixed, monitoring raw material data, production data and product data by using a monitoring and collecting system in the preparation process, and recording and storing the raw material data, production data and product data through a monitoring and recording system. Data collected by the monitoring and collecting system is used as a reference, production is controlled and commanded through the monitoring and controlling system, and the monitoring and recording system records and stores the data and sends the data to the monitoring and analyzing system for statistical analysis and machine learning training. Key links such as raw material parameters, environmental process parameters and intermediate product and finished product quality data are monitored online in real time through the monitoring and collecting system, the production dynamic state is comprehensively mastered, and it is guaranteed that all procedures are strictly executed according to the process requirements.
Owner:QINGDAO BOLIN BIOLOGICAL TECH CO LTD

Anti-FGFR2 antibodies in combination with chemotherapy agents in cancer treatment

PendingJP2025004195ADigestive systemMicrobiological testing/measurementAntiendomysial antibodiesFibroblast growth factor receptor 2
To provide a method of treating gastric cancer in a subject.SOLUTION: The method comprises administering, to a subject having gastric cancer, a therapeutically effective amount of an anti-fibroblast growth factor receptor 2 IIIb (anti-FGFR2-IIIb) antibody and modified FOLFOX6 (mFOLFOX6) chemotherapy (oxaliplatin, leucovorin, 5-fluorouracil).SELECTED DRAWING: Figure 1
Owner:FIVE PRIME THERAPEUTICS INC

Application of dauricine in preparation of medicine for inhibiting ovarian cancer SKOV3 cell proliferation and treating ovarian cancer

The invention relates to the technical field of biological medicines, in particular to application of dauricine in preparation of medicines for inhibiting ovarian cancer SKOV3 cell proliferation and treating ovarian cancer. The invention finds that dauricine has a remarkable inhibition effect on drug-resistant ovarian cancer cells, the dauricine has a clear dose-dependent relationship on the inhibition activity of the ovarian cancer cells SKOV3 in a concentration range of 1-50 mu M, and the IC50 value is 2 mu M. Meanwhile, the effect of inhibiting SKOV3 cell proliferation of the dauricine can be remarkably improved by combining the dauricine with paclitaxel or 5-fluorouracil. Therefore, dauricine can be used for preparing medicines for inhibiting ovarian cancer SKOV3 cell proliferation and improving ovarian cancer multidrug resistance, and has a good clinical application prospect.
Owner:RES INST OF ZHEJIANG UNIV TAIZHOU

Application of quercetin or derivative thereof in anti-vocal cord fibrosis medicine and preparation

The invention relates to an application of Quercetin (QUE) or a derivative thereof in a medicine for resisting vocal cord fibrosis and a preparation of the Quercetin or the derivative thereof. The quercetin can significantly inhibit abnormal deposition of extracellular matrix (ECM) after vocal cord injury, improve reduction of hyaluronic acid (HA) and elastic fibers (EF), and reduce overexpression of type I collagen (COL1A1) and fibronectin (FN1). Besides, by regulating PI3K / AKT and MAPK signal channels, the quercetin inhibits proliferation and migration of fibroblasts and promotes apoptosis of the fibroblasts, so that vocal cord fibrosis is effectively relieved. The invention also provides an application of a preparation of the quercetin and the derivative thereof combined or not combined with other anti-fibrosis drugs (such as 5-fluorouracil and dexamethasone) in treatment of vocal cord fibrosis, wherein the dosage forms of the preparation comprise an oral preparation, an injection, a spray or a local gel preparation.
Owner:LP PHARM (XIAMEN) CO LTD

Application of minocycline in preparation of anti-tumor synergist

ActiveCN120695014ATetracycline active ingredientsAntineoplastic agentsSide effectFluorouracil/Gemcitabine
The invention belongs to the technical field of medicines, and relates to application of minocycline in preparation of an anti-tumor synergist. The minocycline is used as an anti-tumor synergist and has a synergistic effect with the 5-fluorouracil and the gemcitabine, so that the curative effect of the anti-tumor medicine is remarkably enhanced, the dosage of the anti-tumor medicine is reduced, and the body side effect caused by the anti-tumor medicine or the damage to normal tissue cells is reduced.
Owner:GUANGZHOU YANLORD PHARM TECH CO LTD

Use of oxaliplatin in the preparation of medicaments for the treatment of cancer

The present application relates to the application of ocanin in the preparation of anti-tumor drugs, and the ocanin is used in the anti-tumor drugs alone or in combination with 5-fluorouracil, and the concentration of the ocanin used in the preparation of anti-intestinal cancer drugs is 20-500 uMol. It is found that the ocanin can inhibit the growth of intestinal cancer cells in vivo and in vitro, and the naked mice have good tolerance to the natural compound. The ocanin has better anti-intestinal cancer effect than other extracts of goldeneye and devil's needle, and has better anti-cancer effect and smaller toxicity than the current conventional intestinal cancer drug 5-fluorouracil. Therefore, the ocanin can be developed into a new anti-cancer drug.
Owner:XUZHOU NORMAL UNIVERSITY

Combined administration of irinotecan lipidosome for treating colorectal cancer

The invention relates to irinotecan liposome combined administration for treating colorectal cancer. Specifically, the invention relates to application of irinotecan lipidosome combined with oxaliplatin, 5-fluorouracil, calcium folinate and bevacizumab in preparation of medicines for treating colorectal cancer, and the irinotecan lipidosome contains hydrogenated soybean lecithin, polyethylene glycol 2000-distearoyl phosphatidyl ethanolamine and cholesterol.
Owner:JIANGSU HENGRUI MEDICINE CO LTD

5-halouracil-modified double-stranded nucleic acids and their use in treatment of cancer

The present disclosure provides double stranded nucleic acid compositions incorporating uracil, gemcitabine, and methotrexate (MTX). More specifically, the present disclosure reveals that modification of a double-stranded microRNA nucleotide sequence with 5-fluorouracil, gemcitabine, and methotrexate (MTX) enhances the therapeutic efficacy and tumor specificity of tumor suppression. Thus, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-fluorouracil, gemcitabine, and methotrexate (MTX) incorporated into their nucleic acid sequences, as well as methods of using the same. The disclosure further provides pharmaceutical compositions (e.g., formulations) comprising the modified nucleic acid compositions, and methods for treating cancer, e.g., pancreatic cancer. The method is a platform technology which can be applied to other tumor suppressor genes miRNA and siRNA.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK

PCSK9 inhibitor-based microsatellite stable colorectal cancer combination therapy

The invention discloses a microsatellite stable colorectal cancer combination therapy based on a PCSK9 inhibitor, and belongs to the technical field of cancer treatment. The medicine for treating the microsatellite stable colorectal cancer comprises a PCSK9 inhibitor and a composition, and the composition comprises a PD-1 antibody and / or 5-fluorouracil. The invention provides a combination therapy of a PCSK9 blocking antibody combined with chemotherapy and immunotherapy. The combination therapy comprises a combination of a PCSK9 inhibitor, a PD-1 antibody and 5-FU for treatment of microsatellite stable colorectal cancer. The combination therapy can significantly enhance the sensitivity of the microsatellite stable colorectal cancer to 5-FU chemotherapy.
Owner:GUANGDONG GENERAL HOSPITAL

Glucocorticoid receptor-targeted formulations for the treatment of colorectal cancer and preparation thereof

PCT designated stageWO2025191573A1Organic active ingredientsAntiinfectivesAnticarcinogenTumor regression
The present disclosure provides an anti-cancer lipid-based composition that kills very aggressive colorectal cancer cells. This composition is a concoction of an anti- cancer agent, 5-Fluorouracil and a glucocorticoid receptor (GR)-targeting cationic lipid delivery system, D1X. The uptake studies of these formulations have showed that formulations with dexamethasone enter into nucleus, bind GRE region and upregulate CYP3a5 gene. The intensity of upregulation is better than liposome without dexamethasone. Same results found in in vivo studies, the D1X5-FU shows better tumor regression and survivability than FOLFOX and FOLFIRI. The biodistribution studies showed that D1X5-FU targets only tumor tissues, not other organs. The pilot studies of tumor regression by other liposomal formulations- D1XLeucovorin, D1XOxaliplatin has showed better tumor regression than FOLFOX and FOLFIRI.
Owner:COUNCIL OF SCI & IND RES +1

Use of a pharmaceutical composition comprising GL-V9 and a chemotherapeutic agent as active ingredients for treating tumors

The application discloses application of a pharmaceutical composition taking GL-V9 and a chemotherapeutic drug as active ingredients in treatment of tumors. When GL-V9 is combined with a classical chemotherapeutic drug to treat tumors, a drug synergistic effect can be obviously achieved, and the effect is obviously superior to combination of similar drugs and the chemotherapeutic drug. The chemotherapeutic drugs include 5-fluorouracil; and the tumor types include leukemia, colorectal cancer and lung cancer.
Owner:NANJING QINLING PHARMACEUTICAL TECHNOLOGY CO LTD

Application of saikoside D in preparation of medicine for inhibiting colorectal cancer Caco-2 cell proliferation and treating colorectal cancer

The invention belongs to the technical field of biological medicines, and particularly relates to application of saikoside D in preparation of medicines for inhibiting colorectal cancer Caco-2 cell proliferation and treating colorectal cancer. The invention finds that saikoside D has a remarkable inhibition effect on colorectal cancer cells, and in a concentration range of 1-50 [mu] M, the saikoside D has a definite dose-dependent relationship on the inhibition activity on the proliferation of colorectal cancer Caco-2 cells, and the inhibition activity is higher than that of paclitaxel and 5-fluorouracil. Meanwhile, the combination of saikoside D and paclitaxel can significantly improve the Caco-2 cell proliferation inhibition effect, which may be related to P-gp protein expression inhibition. Therefore, saikosaponin D can be used for preparing the medicine for inhibiting the proliferation of colorectal cancer Caco-2 cells and improving the drug resistance of paclitaxel to colorectal cancer, and has a good clinical application prospect.
Owner:RES INST OF ZHEJIANG UNIV TAIZHOU

tRF5-22-sectca-1, tRF5-22-sectca-1 detection reagents, kits and uses thereof

PendingCN122357548AOncologyChemo therapy
This invention belongs to the field of molecular biology technology, specifically involving tRF5-22-SeCTCA-1, tRF5-22-SeCTCA-1 detection reagents, kits, and their applications. This invention discovers and verifies that tRF5-22-SeCTCA-1 plays a key regulatory role in the process of 5-fluorouracil (5-FU) chemotherapy resistance in colorectal cancer, filling a gap in the research of tRNA-derived fragments (tRFs) in colorectal cancer chemotherapy resistance. It is the first tRF molecule reported to be associated with 5-FU chemotherapy resistance in colorectal cancer, providing a novel molecular target and research direction for predicting chemotherapy resistance in colorectal cancer. This invention also provides a therapeutic strategy targeting tRF5-22-SeCTCA-1 and establishes α-ketoglutarate as an independent reversal agent, providing multi-dimensional technical solutions for the precision diagnosis and treatment of colorectal cancer and the reversal of chemotherapy resistance.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

5-Fluorouracil compound

The present invention provides 5-fluorouracil-derived acetal and hemiaminal ether compounds, their preparation and uses (such as for treating liver diseases or various types of cancers).
Owner:NUCORION PHARMACEUTICALS INC

Method for determining the survival prognosis of a patient suffering from pancreatic cancer

The present invention relates to pancreatic cancer, and more particularly to the survival prognosis of a patient suffering from pancreatic cancer. The invention also aims to determine the benefit to the patient of receiving a pancreatic cancer treatment, particularly a treatment based on 5-fluorouracil. The invention also relates to a method for monitoring the efficacy of a pancreatic cancer treatment, advantageously of a treatment based on 5-fluorouracil, by implementing the method.
Owner:ACOBIOM

Acylhydrazone compound containing quinazolinone fragment as well as preparation method and application of acylhydrazone compound

The invention discloses an acylhydrazone compound containing a quinazolinone fragment as well as a preparation method and application thereof, and relates to the technical field of medicinal chemistry, the acylhydrazone compound containing the quinazolinone fragment or pharmaceutically acceptable salt, isomer, hydrate, solvate, crystal form and prodrug of the acylhydrazone compound, and the structural formula of the acylhydrazone compound containing the quinazolinone fragment or pharmaceutically acceptable salt, isomer, hydrate, solvate, crystal form and prodrug of the acylhydrazone compound containing the quinazolinone fragment is shown in the specification. According to the invention, acylhydrazone compounds containing quinazolinone fragments are designed and synthesized by utilizing a splicing principle, the compounds are subjected to anticancer activity test, and the compounds with anticancer activity superior to that of 5-fluorouracil are screened out from the acylhydrazone compounds.
Owner:BOZHOU UNIV

Application of miR-30a-5p and target gene thereof in diagnosis and treatment of hepatocellular carcinoma

The invention discloses application of miR-30a-5p and a target gene thereof in diagnosis and treatment of hepatocellular carcinoma, according to the scheme, tests prove that the toxic and side effects of an anti-hepatocellular carcinoma drug 5-fluorouracil can be remarkably reduced by reducing the expression quantity of miR-30a-5p, so that miR-30a-5p becomes a potential target for screening drugs for reducing the toxic and side effects of 5-fluorouracil; and when the target gene Thbs2 of the miR-30a-5p is in low expression, immunohistochemical (IHC) staining data is further retrieved from an HPA database, and the expression level of the Thbs2 obtained from the perspective of protein is medium in staining in normal liver tissues and relatively high in staining in liver cancer tissues, so that the Thbs2 can be used as a molecular marker for liver cancer diagnosis. The research provides an important basis for clinical early diagnosis and differential diagnosis of liver cancer and effective observation and alleviation of side effects of anti-cancer drugs, provides a brand new idea for accurate diagnosis of liver cancer and alleviation of side effects of anti-cancer drugs from the molecular level, and expands the cognition of the occurrence and development mechanism of liver cancer in the theoretical level. The obvious practical value and transformation potential are also shown in clinical application.
Owner:FUJIAN AGRI & FORESTRY UNIV

Probiotics mixtures and methods of use thereof for treating cancers

A probiotic composition for treating or preventing metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma(MASLD-HCC) or colorectal cancer, comprises one or more microbiota selected from a group consisting of Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus rhamnosus GG, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium breve, Bifidobacterium animalis subsp. Lactis, Streptococcus thermophilus or any combination thereof. The probiotic composition demonstrates improved therapeutic effects when combined with low-dose Sorafenib for MASLD-HCC and outperforms 5-Fluorouracil in colorectal cancer models.
Owner:THE UNIVERSITY OF HONG KONG

Capecitabine prodrug for reducing liver metabolism burden and application of capecitabine prodrug

The invention provides a capecitabine prodrug for reducing liver metabolism burden and application thereof, a derivative formed by introducing a masking group R capable of enzymolysis or chemical hydrolysis into 5 '-hydroxyl or N-amino of a capecitabine molecule, and the R is selected from amino-acid ester, phosphate, polyethylene glycol chain or cholic acid conjugation group. The prodrug can be selectively activated in intestinal tracts or tumor tissues through a non-UGT1A1 dependent pathway, and 5-fluorouracil is finally released through metabolism. Due to the characteristic, the competitive inhibition of the prototype capecitabine on liver UGT1A1 enzyme is obviously reduced, and the interference on bilirubin binding and excretion pathways is fundamentally reduced. The pharmaceutical composition disclosed by the invention is suitable for patients with UGT1A1 gene defects or liver insufficiency. While good anti-tumor activity is maintained, the hepatotoxicity is remarkably reduced, the medication safety is improved, and good clinical application prospects are achieved.
Owner:FIRST AFFILIATED HOSPITAL OF XINJIANG MEDICAL UNIVERSITY +1

Combinations and therapies comprising fluorouracil and anlotinib

The present invention relates to the use of fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of cancer in a patient. The invention also relates to compositions, pharmaceutical compositions and pharmaceutical formulations comprising fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV